IsoRay inks $8m private placement deal
IsoRay (NYSE:ISR) has inked a private placement deal worth approximately $8.3 million, according to an SEC filing posted this week. Through the deal, Richland, Wash.-based IsoRay is floating 11 million shares of common stock at 75¢ per share with several institutional and accredited investors, according to the filing. The company said it will also offer unregistered warrants to purchase a number of shares equal to 50% of the investors shares at an exercise price of 75¢, exercisable six months after issuance out to 5.5 years, according to an SEC filing. A total of 5.5 million shares will be offered through th...
Source: Mass Device - July 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat IsoRay Source Type: news

IsoRay wins FDA nod for GammaTile brain tumor treatment
IsoRay (NYSE:ISR) said today it won FDA 510(k) clearance for its GammaTile brachytherapy technology designed for treating recurrent brain tumors. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. IsoRay said it had previously inked a collaborative development and ten-year supply agreement for the newly cleared GammaTile with GT Medical Technology, which the company said will be available in the US “in the near future.” “We are ve...
Source: Mass Device - July 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Neurological Oncology Regulatory/Compliance IsoRay Source Type: news

Living With Cancer: Prostate cancer brachytherapy
Prostate cancer brachytherapy: Can radiation pass to others?? Prostate brachytherapy is a form of radiation therapy used to treat prostate cancer. The radioactive "seeds" are implanted into the prostate gland, so that radiation is delivered directly to the prostate, minimizing radiation to the surrounding tissue. Depending on the type of prostate cancer brachytherapy you receive, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 22, 2018 Category: Databases & Libraries Source Type: news

Dr. Gawande tapped to lead Amazon-JPM-Berkshire health play | Personnel Moves – June 21, 2018
The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9. The joint venture said that the newly formed company will be headquartered in Boston, and will operate as an independent entity free from profit-making incentives and constraints. Dr. Gawande also serves as a professor of Harvard Medical School and the Harvard T.H. Chan School of Public Health, and is the founding executive director of health system...
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News AirXpanders Amazon Avantis Medical Systems Inc. Berkshire Hathaway Boston Scientific CHF Solutions Inc. Corindus Vascular Robotics Haemonetics Intuitive Surgical IsoRay JP Morgan Chase medicen Medtronic Source Type: news

CDH Beats Varian in Bid for Embattled Sirtex
Money talked and Sirtex Medical listened. The New South Wales, Australia-based medical device company that provides a targeted internal radiation therapy for certain liver cancers, said its board decided that the competing bid from CDH Investments was superior to the earlier bid it received from Varian. In January, Palo Alto, CA-based Varian offered to pay about $1.3 billion (A$28 a share) to acquire Sirtex, and the two companies entered into an agreement, which Sirtex shareholders were expected to approve on May 7. That was until CDH, a major alternative asset management firm based in Beijing, Chi...
Source: MDDI - June 14, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

CFDA drafts guidance on 3D-printed medical devices
The China Food and Drug Administration (CFDA) has released a draft guidance...Read more on AuntMinnie.comRelated Reading: China clears Elekta's Gamma Knife Icon iCAD scores Chinese OK for balloon applicators ViewRay gets Chinese approval for MRIdian system Celsion wins Chinese approval for ThermoDox study China approves Elekta's Flexitron brachytherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 11, 2018 Category: Radiology Source Type: news

FDA clears Mobius Imaging ’ s Airo Mobile CT imager for pediatric use
Mobius Imaging said yesterday it won FDA 510(k) clearance for its Airo Mobile CT imaging system designed for pediatric applications. The Shirley, Mass.-based company said it previously won FDA 510(k) clearance in 2013 for non-pediatric imaging, and is designed for use in applications supporting brachytherapy, radiation therapy and surgical imaging. The new clearance is an important milestone for the company, Mobius said, expanding the use of the Airo CT system into new segments and applications. “There is an unmet need in being able to provide safe and reliable CT imaging for pediatric patients during various clinica...
Source: Mass Device - April 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Imaging Regulatory/Compliance mobiusimaging Source Type: news

EBRT with Brachytherapy Matches Surgery for Prostate Ca (CME/CE)
(MedPage Today) -- Worse survival without boost in high-risk patients (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 25, 2018 Category: Primary Care Source Type: news

Low Risk for Ureteral Stricture From Cervical Ca Brachytherapy Low Risk for Ureteral Stricture From Cervical Ca Brachytherapy
Neither intracavitary nor interstitial brachytherapy increases the risk for ureteral stricture in locally advanced cervical cancer, except in the setting of hydronephrosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hydronephrosis Ups Risk of Deadly Complication in Cervical Ca (CME/CE)
(MedPage Today) -- Pronounced increase in risk for severe ureteral stricture post-brachytherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 24, 2018 Category: Hematology Source Type: news

Brachytherapy for cervical cancer does not increase the risk of ureteral stricture
(European Society for Radiotherapy and Oncology (ESTRO)) New research presented at the ESTRO 37 conference from two large international trials, shows that intracavitary and interstitial brachytherapy is safe and does not increase the risk of ureteral stricture in cervical cancer patients. Until now, there have been concerns that brachytherapy might increase the risk of this serious, sometimes life-threatening complication, although the treatment itself is associated with better survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2018 Category: Cancer & Oncology Source Type: news

Selective internal radiation therapy (SIRT) fails to extend survival in the SORAMIC study palliative cohort
(European Association for the Study of the Liver) ILC 2018: The addition of SIRT to sorafenib in patients with advanced hepatocellular carcinoma was associated with no overall survival benefits compared with sorafenib alone, but may offer benefits in some subgroups of patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2018 Category: Cancer & Oncology Source Type: news

Varian Medical releases new Velocity cancer imaging software
Varian Medical (NYSE:VAR) said today it launched an FDA-cleared version of its Velocity cancer imaging software, including a new Rapidsphere module. The newly launched Velocity 4.0’s Rapidsphere module is designed for Y90 selective internal radiation therapy dosimetry analysis and provides improved information on tumor responses and normal-tissue toxicity for patients undergoing SIRT, the Palo Alto, Calif.-based company said. The Velocity 4.0 software includes the company’s Velocity M3i multi-modality motion imaging component, the Velocity Aria sync component and the Velocity tumor & dose tracking comp...
Source: Mass Device - April 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging Oncology Software / IT Varian Medical Systems Source Type: news

High-dose radiotherapy lowers prostate cancer recurrence
Increasing the radiotherapy dose for prostate cancer patients reduced their...Read more on AuntMinnie.comRelated Reading: Societies release guideline for localized prostate cancer Shortened RT works for low-risk prostate cancer patients ASTRO: Prostate cancer has 3 molecular subtypes C4 touts MRI-guided prostate brachytherapy study Experience counts in treating prostate cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 26, 2018 Category: Radiology Source Type: news

Brachytherapy Boost Tops Surgery for Prostate Ca
(MedPage Today) -- Lower disease-specific mortality in those with Gleason 9-10 tumors (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 6, 2018 Category: Hematology Source Type: news

AMIC pans 'site neutral' payment plan
The Access to Medical Imaging Coalition (AMIC) is taking a hammer to President...Read more on AuntMinnie.comRelated Reading: AMIC calls on MedPAC to back appropriate use criteria AMIC warns of prior authorization threat AMIC reports progress on RadioGel FDA clearance President's 2016 budget: More of the same for healthcare? AMIC nets brachytherapy-related patent (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 22, 2018 Category: Radiology Source Type: news

Estimated Biopsy Rate Varies After Breast Cancer Treatment
Incidence of breast biopsy higher among women treated with brachytherapy versus whole - breast irradiation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 2, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Radiology, Surgery, Journal, Source Type: news

Varian to Acquire Embattled Sirtex for $1.3B
Varian Medical Systems has revealed plans to acquire interventional oncology specialist Sirtex Medical for $1.3 billion. The proposed acquisition comes about a year after the New South Wales, Australia-based company fired CEO Gilman Wong, following an investigation into his share trading. In January 2017, the Sydney Morning Herald reported Wong was terminated after an investigation revealed he received $2.1 million from the sale of shares in Sirtex about one day after he told investors at the company’s annual general meeting that the company expected “double-digit” dose sales in 2017. Wong was replaced ...
Source: MDDI - February 1, 2018 Category: Medical Devices Authors: Omar Ford Tags: Medical Device Business Source Type: news

Advanced Medical Isotope changes name
Medical isotope developer Advanced Medical Isotope has changed its name to...Read more on AuntMinnie.comRelated Reading: AMIC reports progress on RadioGel FDA clearance AMIC resubmits Y-90 RadioGel to FDA AMIC nets brachytherapy-related patent AMIC looks for European investors AMIC and GSG form strategic alliance (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 2, 2018 Category: Radiology Source Type: news

Hospitals Not Using Cervical Brachytherapy Because of Cost Hospitals Not Using Cervical Brachytherapy Because of Cost
The high cost of brachytherapy discourages many centers from offering this potentially curative procedure for the treatment of cervical cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A gold-standard cancer treatment is in decline, and money may be why
(University of Virginia Health System) Offering brachytherapy for locally advanced cervical cancer ends up costing hospitals money, potentially explaining its declining use even though it's considered the most effective treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2017 Category: Cancer & Oncology Source Type: news

Cianna debuts ScoutCare program
Brachytherapy firm Cianna Medical is launching its ScoutCare support program...Read more on AuntMinnie.comRelated Reading: Cianna touts Scout research Cianna nets FDA OK for radar system Cianna highlights SAVI Scout results at SBI Cianna advances 2 SAVI Scout studies Cianna nets FDA OK for SAVI Scout (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 6, 2017 Category: Radiology Source Type: news

7 medtech stories we missed this week: Oct. 27, 2017
[Image from unsplash.com]From RadiaDyne’s FDA expansion to NuVasive launching its new implants, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA expands indications for RadiaDyne’s OARtrac dose monitor RadiaDyne announced in an Oct. 24 press release that it has received additional FDA clearance for its upcoming OARtrac. The OARtrac allows physicians to routinely monitor brachytherapy radiation dose as well as being able to reuse the OARtrac Plastic Scintillating Detector sensor cable no more than five times on one patient. 2. FDA clears Ortek’s e...
Source: Mass Device - October 27, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Catheters Dental Diagnostics Food & Drug Administration (FDA) Imaging Implants Neurological Research & Development Alcyone Lifesciences Implanet MedTech Nuvasive Ortek Therapeutics radiadyne Tau Consortium Varian Medical Syst Source Type: news

Cleveland Clinic leads development of new guidelines for radiation in breast cancer
(Cleveland Clinic) Cleveland Clinic researcher Chirag Shah, M.D., led the development of updated guidelines for the appropriate and safe utilization of accelerated partial-breast irradiation (APBI). The guidelines are published online in the journal, Brachytherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2017 Category: Cancer & Oncology Source Type: news

In High-Risk Endometrial Cancer, Adding Chemo No Help, but … In High-Risk Endometrial Cancer, Adding Chemo No Help, but …
Vaginal cuff brachytherapy plus chemotherapy was compared to standard radiation therapy alone. The results disappointed, but there is a caveat.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IsoRay revenues climb in Q4
Growth in its number of customers helped medical isotope developer IsoRay to...Read more on AuntMinnie.comRelated Reading: IsoRay highlights cesium-131 brachytherapy research IsoRay touts prostate cancer treatment data FDA responds to IsoRay's GammaTile 510(k) Court approves IsoRay class-action settlement IsoRay agrees to settle shareholder lawsuit (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 29, 2017 Category: Radiology Source Type: news

ASTRO: High - Dose Brachytherapy Effective With Four 7 Gy Fractions
Better tumor control than with two 9 Gy fractions among patients with locally advanced cervical cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 28, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Radiology, Conference News, Source Type: news

Higher-Dose RT Ups Local Control in Cervical Cancer Higher-Dose RT Ups Local Control in Cervical Cancer
High-dose brachytherapy was more effective for managing locally advanced cervical cancer, but did not improve overall survival compared to lower-dose therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IsoRay highlights cesium-131 brachytherapy research
Medical isotope developer IsoRay is highlighting research that suggests the...Read more on AuntMinnie.comRelated Reading: IsoRay touts prostate cancer treatment data FDA responds to IsoRay's GammaTile 510(k) Court approves IsoRay class-action settlement IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 26, 2017 Category: Radiology Source Type: news

IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference
9-Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131 RICHLAND, Wash., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator ... Devices, Oncology IsoRay, brachytherapy, radiotherapy, cesium, iodine, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2017 Category: Pharmaceuticals Source Type: news

International trial confirms safety, effectiveness of HDR brachytherapy for cervical cancer
(American Society for Radiation Oncology) Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gray (Gy) each than following two, 9-Gy fractions of high-dose-rate (HDR) brachytherapy, but neither overall survival nor severe treatment-related side effects differed between the treatment groups. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2017 Category: International Medicine & Public Health Source Type: news

Trial confirms pelvic radiation as standard of care for high-risk endometrial cancer
(American Society for Radiation Oncology) In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal cuff brachytherapy plus chemotherapy when compared with pelvic radiation therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2017 Category: Cancer & Oncology Source Type: news

7 medtech stories we missed this week: Sept. 8, 2017
[Image from unsplash.com]From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating a pediatric capability for its BrainScope One medical neurotechnology. The technology is an FDA-cleared handheld medical device that is designed to assess the full spectrum of traumatic brain injury. The company sa...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Imaging mHealth (Mobile Health) Neurological Regulatory/Compliance Research & Development Spinal AliveCor Bonesupport Bra Source Type: news

No Difference in Toxicity for 6 - , 2 - Fraction HDR in Prostate Cancer
Urinary, sexual toxicity similar with 6 - , 2 - fraction high - dose - rate brachytherapy regimen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 7, 2017 Category: Cancer & Oncology Tags: Oncology, Radiology, Urology, Journal, Source Type: news

C4 gets new FDA clearance for Sirius MRI marker
Image-guided technology developer C4 Imaging announced that the U.S. Food and...Read more on AuntMinnie.comRelated Reading: C4 touts MRI-guided prostate brachytherapy study C4 raises $1.3M for multimodality marker C4 Imaging nets 510(k) clearance for MRI marker (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 6, 2017 Category: Radiology Source Type: news

iCad wins Chinese approval for Xoft Axxent balloon applicators
iCad (NSDQ:ICAD) said today its Xoft Axxent balloon applicators have been cleared by the China Food & Drug Administration for treating early-stage breast cancer. The Nashua, N.H.-based company’s Xoft Axxent balloon applicators are part of its Xoft Axxent electronic brachytherapy system designed to perform intraoperative radiation therapy in early-stage breast cancer patients who meet specific selection criteria. The balloon applicator is used to deliver a single dose of radiation to the lumpectomy cavity to target cancer cells directly and limit exposure to health surrounding tissue, iCad said. “The Xo...
Source: Mass Device - August 30, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Women's Health iCad Inc. Source Type: news

ASTRO supports US Nuclear Regulatory Commission final rule
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) applauds the United States Nuclear Regulatory Commission for yesterday's announcement of a final rule that updates the definition of medical events for permanent implant brachytherapy and protects patients' access to this treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2017 Category: International Medicine & Public Health Source Type: news

7 medtech stories we missed this week: August 11, 2017
[Image from unsplash.com]From Xtant Medical’s 510(k) extension to Varian Medical’s distribution deal, here are seven medtech stories we missed this week but thought were still worth a mention. 1. FDA extends Xtant Medical’s 510(k) for Calix C spinal implant Xtant Medical announced in an Aug. 9 press release that the FDA has cleared its product line extensions for the Calix-C cervical inter body cages. The clearance allows for two larger footprints to be added for use with allograft. The Calix-C Cervical Interbody Spacer is designed for spinal fusion procedures at level one in patients who are skeletally m...
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiovascular Clinical Trials Food & Drug Administration (FDA) Oncology Regulatory/Compliance Spinal Surgical Apifix Cardiac Science Hip Innovation Life Spine Inc. MedTech Pentax Medical Varian Medical Systems Xtant M Source Type: news

Varian Medical Systems Signs Brachytherapy Applicator Distribution Agreement with Bionix Radiation Therapy
PALO ALTO, Calif., Aug. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced it has signed an agreement with Bionix® Radiation Therapy to distribute Bionix brachytherapy applicators. Varian will marke... Devices, Oncology, Distribution Varian Medical Systems, Bionix Radiation Therapy, brachytherapy applicators (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 9, 2017 Category: Pharmaceuticals Source Type: news

IsoRay touts prostate cancer treatment data
Medical isotope developer IsoRay is highlighting data that show that brachytherapy...Read more on AuntMinnie.comRelated Reading: FDA responds to IsoRay's GammaTile 510(k) Court approves IsoRay class-action settlement IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 1, 2017 Category: Radiology Source Type: news

Right-Sided Metastatic CRC Benefits From Adding SIRT to Chemotherapy
Patients with colorectal cancer that has metastasized to the liver derive a significant benefit from selective internal radiation therapy (SIRT) combined with chemotherapy if their primary tumor is a right-sided tumor, but not if it is a left-sided primary tumor. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

IsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer
Public Accounting Background RICHLAND, Wash., July 7, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatme... Devices, Oncology, Personnel IsoRay, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 7, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Colorectal cancer: Adding SIRT to chemotherapy boosts survival
For patients with advanced colorectal cancer, new research suggests that adding selective internal radiation therapy to chemotherapy may prolong survival. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 7, 2017 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

FDA responds to IsoRay's GammaTile 510(k)
The U.S. Food and Drug Administration (FDA) has issued a response to medical...Read more on AuntMinnie.comRelated Reading: Court approves IsoRay class-action settlement IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results IsoRay revenue edges higher, but net loss grows (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2017 Category: Radiology Source Type: news

FDA requests more info on IsoRay ’ s GammaTile
IsoRay (NYSE:ISR) said today that the FDA requested additional data on the company’s pending 510(k) application for its GammaTile radiation therapy system. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. “This is a good outcome for the novel GammaTile product. With the completion of additional testing anticipated by the end of 2017, we project potential 510(k) clearance of the GammaTile product in the 1st half of 2018 which would all...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology IsoRay Source Type: news

IsoRay Receives FDA Response to 510(k) Application for GammaTile(TM)
Additional Testing for GammaTile™ Planned for Completion by Year-End 2017 RICHLAND, Wash., July 6, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medi... Devices, Oncology, FDA IsoRay, GammaTile, radiotherapy, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2017 Category: Pharmaceuticals Source Type: news

New Analysis Reveals First-Line Treatment Data on SIR-Spheres(R) Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided primary tum... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin, microspheres, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2017 Category: Pharmaceuticals Source Type: news

Robot-assisted Implantation of Brachytherapy Catheters Promising in Bladder Cancer Robot-assisted Implantation of Brachytherapy Catheters Promising in Bladder Cancer
Robot-assisted laparoscopic (RAL) implantation of brachytherapy catheters (BTC) is a minimally invasive alternative to open retropubic surgery, researchers from the Netherlands report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 27, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

IsoRay touts another ‘ 100% ’ study
IsoRay (NYSE:ISR) today released data from a study of its Cesium-131 brachytherapy for treating patients with large brain metastases, touting a 100% freedom from local progression. Results from the study were published in the International Journal of Radiation Oncology, Biology, Physics, the Richland, Wash.-based company said. In the study, researchers assessed the impact of low-dose rate Cesium-131 brachytherapy on local control and radionecrosis in 42 patients treated for a total of 46 large brain metastases. Patients in the trial underwent surgical resection with intra-operative palcement of standard Cesium-131 see...
Source: Mass Device - June 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology IsoRay Source Type: news

Elekta points to study of older lung cancer patients
Radiation oncology vendor Elekta is highlighting research that found stereotactic...Read more on AuntMinnie.comRelated Reading: Elekta debuts MR-linac radiation therapy system at ESTRO Varian, Elekta settle patent dispute Elekta nabs Canadian Medical Device License Elekta gets FDA clearance for brachytherapy applicator Elekta to support ASTRO safety initiative (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2017 Category: Radiology Source Type: news